Darolutamide versus abiraterone acetate-based triplets in patients with hormone-sensitive prostate cancer: real-world, head-to-head comparison from the ARON-3 study. - Rescigno P; Taha T; Fita MJ; Matthews D; Fujita K; Lolli C; DI Costanzo F; Juárez A; Ürün Y; Yazgan SC; Li H; Facchini G; et al. (Minerva urology and nephrology, 2026)